11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Myleran

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C! C!
C! C!

Busulfan

Busulfan

Klass : C!

Visa all info

Skriv ut

Kontakta oss

  1. Radkiewicz, C. Sex differences in cancer risk and survival. [dissertation]. Dept of Medical Epidemiology and Biostatistics: Karolinska Institutet; 2019.

  2. Edgren G, Liang L, Adami HO, Chang ET. Enigmatic sex disparities in cancer incidence. Eur J Epidemiol. 2012;27(3):187-96.

  3. McCune JS, Bemer MJ, Barrett JS, Scott Baker K, Gamis AS, Holford NH. Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization. Clin Cancer Res. 2014;20(3):754-63.

  4. Berger U, Maywald O, Pfirrmann M, Lahaye T, Hochhaus A, Reiter A et al. Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia. 2005;19(6):984-9.

  5. Wong SP, Tan SM, Lee CS, Law KB, Lim YAL, Rajasuriar R. Prospective longitudinal analysis of clinical and immunological risk factors associated with oral and gastrointestinal mucositis following autologous stem cell transplant in adults. Support Care Cancer. 2023;31(8):494.

  6. Weinhard S, Wiedemann A, Leheup B, Dalle JH, Lebon Labich B, Pochon C. Pubertal outcomes of children transplanted with allogeneic stem cells after myeloablative total body irradiation or busulfan: Influence of age and sex is confirmed, while a role of chronic graft-versus-host disease in delayed puberty onset is revealed. Pediatr Transplant. 2020;24(6):e13773.

  7. Ferrari S, Sundby Hall K, Luksch R, Tienghi A, Wiebe T, Fagioli F et al. Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. Ann Oncol. 2011;22(5):1221-1227.

  8. Paioli A, Luksch R, Fagioli F, Tamburini A, Cesari M, Palmerini E et al. Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age. J Chemother. 2014;26(1):49-56.

  9. Busulfan Fresenius Kabi (busulfan). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2021-04-26, cited 2024-01-21]

  1. Radkiewicz, C. Sex differences in cancer risk and survival. [dissertation]. Dept of Medical Epidemiology and Biostatistics: Karolinska Institutet; 2019.
  2. Edgren G, Liang L, Adami HO, Chang ET. Enigmatic sex disparities in cancer incidence. Eur J Epidemiol. 2012;27(3):187-96.
  3. McCune JS, Bemer MJ, Barrett JS, Scott Baker K, Gamis AS, Holford NH. Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization. Clin Cancer Res. 2014;20(3):754-63.
  4. Berger U, Maywald O, Pfirrmann M, Lahaye T, Hochhaus A, Reiter A et al. Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia. 2005;19(6):984-9.
  5. Wong SP, Tan SM, Lee CS, Law KB, Lim YAL, Rajasuriar R. Prospective longitudinal analysis of clinical and immunological risk factors associated with oral and gastrointestinal mucositis following autologous stem cell transplant in adults. Support Care Cancer. 2023;31(8):494.
  6. Weinhard S, Wiedemann A, Leheup B, Dalle JH, Lebon Labich B, Pochon C. Pubertal outcomes of children transplanted with allogeneic stem cells after myeloablative total body irradiation or busulfan: Influence of age and sex is confirmed, while a role of chronic graft-versus-host disease in delayed puberty onset is revealed. Pediatr Transplant. 2020;24(6):e13773.
  7. Ferrari S, Sundby Hall K, Luksch R, Tienghi A, Wiebe T, Fagioli F et al. Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. Ann Oncol. 2011;22(5):1221-1227.
  8. Paioli A, Luksch R, Fagioli F, Tamburini A, Cesari M, Palmerini E et al. Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age. J Chemother. 2014;26(1):49-56.
  9. Busulfan Fresenius Kabi (busulfan). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2021-04-26, cited 2024-01-21]